Dear Valued Customers,

Due to our strategic development of the Company, we are pleased to announce the change of Company Name as follow:

Company Name: 
STADA-VN JOINT VENTURE CO., LTD. officially changed its name to STELLAPHARM J.V. CO., LTD. (effective as of August 19, 2019)

Branch Name: 
STADA-VN JOINT VENTURE CO., LTD, Binh Duong Branch officially changed its name to STELLAPHARM J.V. CO., LTD. – BRANCH 1 (effective as of August 26, 2019)

Address, Tax code, Telephone/Fax Number remains unchanged.


The changing of our company name and its branch name does not affect to current business activities and product quality of the Company. We would like to take this opportunity to express our sincere thanks to you for all valuable support and cooperation during the past time.


STELLAPHARM is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-viral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An Town, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: | W:

You May like

14 Jun 2016


On 15 March 2016, the fourth EU-GMP Inspection was conducted at STADA – VN J.V. Co., Ltd., Binh Duong Branch, currently known as STELLAPHARM J.V. Co., Ltd. – Branch 1

18 Feb 2019


Lesovir is manufactured by its EU-GMP facility and distributed via exclusive distributor, Khuong Duy Pharma Co., Ltd. The product is a fixed-combination preparation of Ledipasvir 90 mg and Sofosbuvir 400 mg) is an oral drug used for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection which are common types in Asia including Vietnam.